Showing results (441-450 of 504) with videos related to

Sort By:
Pageof 51
Pain|November 7, 2019
Implications of the putamen in pain and motor deficits in complex regional pain syndromeMonica Azqueta-Gavaldon, Andrew M Youssef, Claudia Storz, et al.
Frontiers in Human Neuroscience|October 24, 2018
Morphine Attenuates fNIRS Signal Associated With Painful Stimuli in the Medial Frontopolar Cortex (medial BA 10)Ke Peng, Meryem A Yücel, Sarah C Steele, et al.
Journal of Personalized Medicine|October 27, 2022
Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?Kenneth Blum, Catherine A Dennen, Igor Elman, et al.
Experimental and Clinical Psychopharmacology|October 8, 2008
Retrospective accounts of initial subjective effects of opioids in patients treated for pain who do or do not develop opioid addiction: a pilot case-control studyCorey M Bieber, Kathrine Fernandez, David Borsook, et al.
Psycho-Oncology|December 18, 2024
Scanxiety and Fear of Recurrence in Young Adult Female Breast and Gynaecological Cancer Survivors: Investigating Shared MechanismsDiya S Patel, Sarah N Webster, Emily J Dowling, et al.
JMIR Rehabilitation and Assistive Technologies|November 23, 2020
Virtual Reality in Pain Rehabilitation for Youth With Chronic Pain: Pilot Feasibility StudyAnya Griffin, Luke Wilson, Amanda B Feinstein, et al.
Pain|November 7, 2019
Avoid or engage? Outcomes of graded exposure in youth with chronic pain using a sequential replicated single-case randomized designLaura E Simons, Johan W S Vlaeyen, Lies Declercq, et al.
Pain|August 25, 2023
A randomized controlled trial of graded exposure treatment (GET living) for adolescents with chronic painLaura E Simons, Lauren E Harrison, Derek B Boothroyd, et al.
Journal of Personalized Medicine|December 23, 2022
Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) TestingEdward Justin Modestino, Kenneth Blum, Catherine A Dennen, et al.
Drug Discovery Today|May 15, 2012
Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for painDavid Borsook, Jaymin Upadhyay, Michael Klimas, et al.
Pageof 51